Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 318,754 | 319,290 | 335,035 | 264,306 | 224,818 |
| Cost of Goods | 85,370 | 54,869 | 51,266 | 41,116 | 40,808 |
| Gross Profit | 233,384 | 264,421 | 283,769 | 223,190 | 184,010 |
| Operating Expenses | 463,585 | 415,097 | 472,649 | 481,346 | 376,504 |
| Operating Income | -229,831 | -149,807 | -188,614 | -258,040 | -191,686 |
| Interest Expense | 30,035 | 28,955 | 29,913 | 41,084 | 42,609 |
| Other Income | -14,343 | 6,400 | 11,506 | -106,819 | -40,378 |
| Pre-tax Income | -274,209 | -172,362 | -207,021 | -405,943 | -274,673 |
| Income Tax | 1,815 | 1,739 | 472 | -23 | 2,729 |
| Net Income Continuous | -276,024 | -174,101 | -207,493 | -405,920 | -277,402 |
| Net Income | $-276,024 | $-174,101 | $-207,493 | $-405,920 | $-277,402 |
| EPS Basic Total Ops | -2.21 | -1.40 | -1.69 | -3.32 | -2.29 |
| EPS Basic Continuous Ops | -2.21 | -1.40 | -1.68 | -3.32 | -2.29 |
| EPS Diluted Total Ops | -2.21 | -1.40 | -1.69 | -3.32 | -2.29 |
| EPS Diluted Continuous Ops | -2.21 | -1.40 | -1.68 | -3.32 | -2.29 |
| EBITDA(a) | $-206,384 | $-123,728 | $-204,811 | $-237,390 | $-171,449 |